Product Summary
Teneligliptin Hydrobromide (CAS 906093-29-6, MP-513) is a long-acting oral selective DPP-4 inhibitor API approved in Japan for Type 2 Diabetes Mellitus treatment. Featured excellent water solubility and stable pharmacokinetics, no dose adjustment required for hepatic/renal impaired patients. Our ...
GMP factory supply Teneligliptin hydrobromide Powder high purity CAS 906093-29-6 Teneligliptin
Basic Properties
Trading Properties
Teneligliptin hydrobromide powder
,GMP factory Teneligliptin API
,high purity Teneligliptin hydrobromide
| Item | Details |
|---|---|
| Product Name | Teneligliptin Hydrobromide |
| CAS No. | 906093-29-6 |
| Synonyms | MP-513 Hydrobromide; Tenelia; |
| Chemical Name | (3S,5R)-1-[1-Phenyl-3-methylpyrazol-5-yl]-5-(1,3-thiazolidine-3-carbonyl)piperidin-3-amine 2.5Hydrobromide |
| Molecular Formula | C22H30N6OS⋅2.5HBr |
| Molecular Weight | 628.86 |
| Free Base MW | 426.58 |
| Appearance | White to off-white crystalline powder |
| Purity | ≥99.0% HPLC (JP/EP Pharma Grade) |
| Specific Rotation | [α]D25:-28° ~ -36° (c=0.5, Methanol) |
| Solubility | Water ≥200 mg/mL; DMSO≥100 mg/mL; Sparingly soluble in Ethanol(≈17mg/mL) |
| Storage | Sealed, 2~8℃ dry & away from light; Long-term: -20℃ sealed desiccation |
| Target Enzyme | DPP-4(Dipeptidyl Peptidase 4), IC₅₀≈1nM(human DPP4) |
| Mechanism | Selective competitive DPP-4 inhibitor, prolong endogenous GLP‑1 half-life, boost insulin secretion & suppress glucagon release to lower fasting/postprandial blood glucose |
| Application | 1. API for oral anti-type 2 diabetes tablets(Original brand Tenelia®, Mitsubishi Tanabe Pharma Japan)
|
| Pharmacopoeia Standard | JP 18, In-house Pharma Specification |

Please use our online inquiry contact form below if you have any questions, our team will get back to you as soon as possible.